Genocea Biosciences (LTS:0A51) EBIT: $-36.12 Mil (TTM As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A51 Genocea Biosciences Inc LTS:0A51
16 GF Score
Price $0.00
View Full Analysis

What is Genocea Biosciences EBIT?

Genocea Biosciences LTS:0A51 16 EBIT is $-36.12 Mil as of Mar. 2022. GuruFocus rates LTS:0A51 with a GF Score™ of 16/100.

Genocea Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2022 was $-15.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2022 was $-36.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genocea Biosciences's annualized ROC % for the quarter that ended in Mar. 2022 was -260.99%. Genocea Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -470.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genocea Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was 777.40%.

Genocea Biosciences  (LTS:0A51) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genocea Biosciences's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:

ROC % (Q: Mar. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Mar. 2022 ))/ count )
=-63.092 * ( 1 - 0% )/( (24.083 + 24.266)/ 2 )
=-63.092/24.1745
=-260.99 %

where

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=55.967 - 8.745 - ( 37.148 - max(0, 18.683 - 41.822+37.148))
=24.083

Invested Capital(Q: Mar. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=38.788 - 8.144 - ( 20.137 - max(0, 18.03 - 24.408+20.137))
=24.266

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Genocea Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2021  Q: Mar. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-62.988/( ( (13.261 + max(-7.022, 0)) + (13.496 + max(-6.647, 0)) )/ 2 )
=-62.988/( ( 13.261 + 13.496 )/ 2 )
=-62.988/13.3785
=-470.82 %

where Working Capital is:

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.674) - (8.745 + 1.7 + 1.251)
=-7.022

Working Capital(Q: Mar. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.271) - (8.144 + 1.564 + 1.21)
=-6.647

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genocea Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2022 )
=-36.118/-4.646
=777.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genocea Biosciences EBIT Related Terms

Genocea Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Genocea Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genocea Biosciences EBIT Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.27 -26.79 -38.00 -42.33 -32.08

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.70 -4.03 -3.33 -13.01 -15.75

LTS:0A51 vs FNAM, BXRX, XSNX: EBIT Comparison

For the Biotechnology subindustry, Genocea Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genocea Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's EV-to-EBIT falls into.


LTS:0A51
16GF Score
Genocea Biosciences Inc LTS:0A51
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genocea Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-36.12 Mil mean?
Genocea Biosciences (LTS:0A51) has a EBIT of $-36.12 Mil as of Mar. 2022. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genocea Biosciences.
Is Genocea Biosciences' EBIT too high?
Genocea Biosciences' current EBIT is $-36.12 Mil. Overall, Genocea Biosciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Genocea Biosciences' EBIT compare to FNAM and BXRX?
Genocea Biosciences' EBIT of $-36.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genocea Biosciences. Genocea Biosciences's current EBIT is $-36.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genocea Biosciences stock overvalued right now?
Genocea Biosciences (LTS:0A51) has a current EBIT of $-36.12 Mil. The current EBIT is $-36.12 Mil. Genocea Biosciences' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Genocea Biosciences (LTS:0A51), the current EBIT is $-36.12 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genocea Biosciences Business Description

Address 100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
16GF Score

Get the complete analysis for LTS:0A51

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price